Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga

Ono Pharmaceutical netted double-digit growth in the April-June first quarter of FY2023 as it continued to see steady growth of its PD-1 inhibitor Opdivo (nivolumab) and SGLT2 inhibitor Forxiga (dapagliflozin). In the three-month period, the company’s consolidated sales grew 12.5%...read more